Pathogen inactivation in labile blood products: Transfusion safety and economic impact;Inactivation des agents pathogènes dans les produits sanguins labiles: Sécurité transfusionnelle et impact économique

Bulletin de l'Academie Nationale de Medecine

Volumn 190, Issue 1, 2006, Pages 169-188

  Cazenave, Jean Pierre ^a   Bourel, Michel ^b   Caen, Jacques ^b   Dirheimer, Guy ^b   Vacheron, André ^b   Sansonetti, Philippe ^b   Michel Briand, Yvon ^b  

^a ACADÉMIE NATIONALE DE MÉDECINE   (France)

^b NONE

Author keywords

Blood platelets; Blood transfusion; Blood borne; Erythrocytes; Pathogens isolation and purification; Public health economics

Indexed keywords

EID: 33745789223     PISSN: 00014079     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0001-4079(19)33359-x     Document Type: Article

References (48)

1. BARBARA J. - Why 'Safer than Ever' may not be quite safe enough. Transfus Med Hemother, 2004, 31 Suppl. 1, 2-10.
2. BLAJCHMAN M.A. - Bacterial contamination of cellular blood components: risks, sources and control. Vox Sang, 2004, 87 Suppl. 1, 98-103.
3. ALLAIN J.P., BIANCO C., BLAJCHMAN M.A., BRECHER M.E., BUSCH M., LEIBY D., LIN L., STRAMER S. - Protecting the blood supply from emerging pathogens: the role of pathogen inactivation. Transfus. Med. Rev., 2005, 19, 110-126.
4. BLAJCHMAN M.A., GOLDMAN M., WEBERT K.E., VAMVAKAS E.C., HANNON J., DELAGE G. - Proceedings of a consensus conference: the screening of blood donors for variant CJD. Transfus. Med. Rev., 2004, 18, 73-92.
5. AUBUCHON J.P. - Pathogen inactivation in cellular blood components: clinical trials and implications of introduction to transfusion medicine. Vox Sang, 2002, 83 Suppl 1, 271-275.
6. CORASH L. - Inactivation of viruses, bacteria, protozoa and leukocytes in platelet and red cell concentrates. Vox Sang, 2000, 78 Suppl 2, 205-210.
7. PILLONEL I, LAPERCHE S. - Trends in risk of transfusion-transmitted viral infections (HIV, HCV, HBV) in France between 1992 and 2003 and impact of nucleic acid testing (NAT). Euro. Surveill., 2005, 10, 5-6.
8. BLAJCHMAN M.A., GOLDMAN M., BAEZA F. - Improving the bacteriological safety of platelet transfusions. Transfus. Med. Rev., 2004, 18, 11-24.
9. REBIBO D., HAUSER L., SLIMANI A., HERVE P., ANDREU G. - The French Haemovigilance System: organization and results for 2003. Transfus. Apheresis. Sci., 2004, 31, 145-153.
10. WOLLOWITZ S. - Targeting DNA and RNA in pathogens: mode of action of amotosalen HCI. Transfus. Med. Hemother., 2004, 31 Suppl. 1, 11-16.
11. CIARAVINO V., MCCULLOUGH T., CIMINO G., SULLIVAN T. - Preclinical safety profile of plasma prepared using the INTERCEPT Blood System. Vox Sang, 2003, 85, 171-182.
12. JANETZKO K., LIN L., EICHLER H., MAYAUDON V., FLAMENT J., KLUTER H. - Implementation of the INTERCEPT Blood System for Platelets into routine blood bank manufacturing procedures: evaluation of apheresis platelets. Vox Sang, 2004, 86, 239-245.
13. CAZENAVE J.P., DAVIS K., CORASH L. - Design of clinical trials to evaluate the efficacy of platelet transfusion: the euroSPRITE trial for components treated with Helinx technology. Semin. Hematol, 2001, 38 Suppl 11, 46-54.
14. CORASH L. - Pathogen reduction technology: methods, status of clinical trials, and future prospects. Curr. Hematol. Rep., 2003, 2, 495-502.
15. GOODRICH R.P. - The use of riboflavin for the inactivation of pathogens in blood products. Vox Sang, 2000, 78 Suppl 2, 211-215.
16. LIN L., HANSON C.V., ALTER H.J., JAUVIN V., BERNARD K.A., MURTHY K.K., METZEL P., CORASH L. - Inactivation of viruses in platelet concentrates by photochemical treatment with amotosalen and long-wavelength ultraviolet light. Transfusion, 2005, 45, 580-590.
17. LIN L., DIKEMAN R., MOLINI B., LUKEHART S.A., LANE R., DUPUIS K., METZEL P., CORASH L. - Photochemical treatment of platelet concentrates with amotosalen and long-wavelength ultraviolet light inactivates a broad spectrum of pathogenic bacteria. Transfusion, 2004, 44, 1496-1504.
18. GRASS J.A., HEI D.J., METCHETTE K., CIMINO G.D., WIESEHAHN G.P., CORASH L., LIN L. - Inactivation of leukocytes in platelet concentrates by photochemical treatment with psoralen plus UVA. Blood, 1998, 91, 2180-2188.
19. HEI D.J., GRASS J., LIN L., CORASH L., CIMINO G. - Elimination of cytokine production in stored platelet concentrate aliquots by photochemical treatment with psoralen plus ultraviolet A light. Transfusion, 1999, 39, 239-248.
20. GRASS J.A., WAFA T., REAMES A., WAGES D., CORASH L., FERRARA J.L., LIN L. - Prevention of transfusion-associated graft-versus-host disease by photochemical treatment. Blood, 1999, 93, 3140-3147.
21. VAN RHENEN D., GULLIKSSON H., CAZENAVE J.P., PAMPHILON D., LJUNGMAN P., KLUTER H., VERMEIJ H., KAPPERS-KLUNNE M., DE GREEF G., LAFORET M., LIOURE B., DAVIS K., MARBLIE S., MAYAUDON V., FLAMENT J., CONLAN M., LIN L., METZEL P., BUCHHOLZ D., CORASH L.; euroSPRITE trial. - Transfusion of pooled buffy coat platelet components prepared with photochemical pathogen inactivation treatment: the euroSPRITE trial. Blood, 2003, 101, 2426-2433.
22. SNYDER E., RAIFE T, LIN L., CIMINO G., METZEL P., RHEINSCHMIDT M., BARIL L., DAVIS K., BUCHHOLZ D.H., CORASH L., CONLAN M.G. - Recovery and life span of 111indium-radiolabeled platelets treated with pathogen inactivation with amotosalen HCl (S-59) and ultraviolet A light. Transfusion, 2004, 44, 1732-1740.
23. VAN RHENEN D.J., VERMEIJ J., MAYAUDON V., HIND C., LIN L., CORASH L. - Functional characteristics of S-59 photochemically treated platelet concentrates derived from buffy coats. Vox Sang, 2000, 79, 206-214.
24. JANETZKO K., CAZENAVE J.P., KLUTER H., KIENTZ D., MICHEL M., BERIS P., LIOURE B., HASTKA J., MARBLIE S., MAYAUDON V., LIN L., LIN J.S., CONLAN M.G., FLAMENT J. - Therapeutic efficacy and safety of photochemically treated aphaeresis platelets processed with an optimized integrated set. Transfusion, 2005, sous presse.
25. TH, DAVIS K., LIN J.S., METZEL P., CORASH L., KOUTSOUKOS A., LIN L., BUCHHOLZ D.H., CONLAN M.G. - Therapeutic efficacy and safety of platelets treated with a photochemical process for pathogen inactivation: the SPRINT Trial. Blood, 2004, 104, 1534-1541.
26. HAMBLETON J., WAGES D., RADU-RADULESCU L., ADAMS M., MACKENZIE M., SHAFER S., LEE M., SMYERS J., WIESEHAHN G., CORASH L. - Pharmacokinetic study of FFP photochemically treated with amotosalen (S-59) and UV light compared to FFP in healthy volunteers anticoagulated with warfarin. Transfusion, 2002, 42, 1302-1307.
27. RUANE PH., EDRICH R., GAMPP D., KEIL S.D., LEONARD R.L., GOODRICH R.P. - Photochemical inactivation of selected viruses and bacteria in platelet concentrates using riboflavin and light. Transfusion, 2004, 44, 877-885.
28. PEREZ-PUJOL S., TONDA R., LOZANO M., FUSTE B., LOPEZ-VILCHEZ I., GALAN A.M., LI J., GOODRICH R., ESCOLAR G. - Effects of a new pathogen-reduction technology (Mirasol PRT) on functional aspects of platelet concentrates. Transfusion, 2005, 45, 911-919.
29. AUBUCHON J.P., PICKARD C.A., HERSCHEL L.H., ROGER J.C., TRACY J.E., PURMAL A., CHAPMAN J., ACKERMAN S., BEACH K.J. - Production of pathogen-inactivated RBC concentrates using PEN110 chemistry: a Phase I clinical study. Transfusion, 2002, 42, 146-152.
30. LAZO A., TASSELLO J., JAYARAMA V., OHAGEN A., GIBAJA V., KRAMER E., MARMORATO A., BILLIA-SHAVEET D., PURMAL A., BROWN F., CHAPMAN J. -Broad-spectrum virus reduction in red cell concentrates using INACTINE PEN110 chemistry. Vox Sang, 2002, 83, 313-323.
31. PURMAL A., VALERI C.R., DZIK W, PIVACEK L., RAGNO G., LAZO A., CHAPMAN J. - Process for the preparation of pathogen-inactivated RBC concentrates by using PEN110 chemistry: preclinical studies. Transfusion, 2002, 42, 139-145.
32. BENJAMIN R.J., MCCULLOUGH J., MINTZ P.D., SNYDER E., SPONITZ W.D., RIZZO R.J., WAGES D., LIN J-S., WOOD L., CORASH L., CONLAN M.G. - Therapeutic efficacy and safety of red blood cells treated with a chemical process (S-303) for pathogen inactivation: a phase III clinical trial in cardiac surgery patients. Transfusion, 2005, 45, 1739-1749.
33. ENGELFRIET C.P., REESINK H.W., KLEIN H.G., AUBUCHON J.P., STRAUSS R.G., KRUSIUS T., MAKI T., REBULLA P., HOGMAN C.F., KNUTSON F., LETOWSKA M., DICKMEISS E., WINTER M., HENN G., MENICHETTI E., MAYR W.R., FLANAGAN P., MARTIN-VEGA C., MASSUET L., WENDEL S., TUREK P., LIN C.K., SHIRATO T. - The future use of pathogen-inactivated platelet concentrates. Vox Sang, 2003, 85, 54-66.
34. FARRUGIA A. - The mantra of blood safety: time for a new tune? Vox Sang, 2004, 86, 1-7.
35. STAGINNUS U., CORASH L. - Economics of pathogen inactivation technology for platelet concentrates in Japan. Int. J. Hematol., 2004, 80, 317-324.
36. VAN HULST M., DE WOLF J.T., STAGINNUS U., RUITENBERG E.J., POSTMA M.J. - Pharmacoeconomics of blood transfusion safety: review of the available evidence. Vox Sang, 2002, 83, 146-155.
37. AUBUCHON J.P., COOPER L.K., LEACH M.F., ZUARO D.E., SCHWARTZMAN J.D. - Experience with universal bacterial culturing to detect contamination of apheresis platelet units in a hospital transfusion service. Transfusion, 2002, 42, 855-861.
38. BOEKHORST P.A., BECKERS E.A., Vos M.C., VERMEIJ H., VAN RHENEN D.J. - Clinical significance of bacteriologic screening in platelet concentrates. Transfusion, 2005, 45, 514-519.
39. BECKERS E.A. - Bacterial contamination of platelet components: remasking risks after introduction of bacterial screening. Vox Sang, 2005, 89, 116.
40. CIARAVINO V., MCCULLOUGH T., CIMINO G. - The role of toxicology assessment in transfusion medicine. Transfusion, 2003, 43, 1481-1492.
41. YEH J.M., BOTTEMAN M., PASHOS C.L., POSTMA M.J., STAGINNUS U. - Economics of transfusion. Infusion Ther Transf. Med., 2002, 29, 218-225.
42. JACKSON B.R., BUSCH M.P., STRAMER S.L., AUBUCHON J.P. - The cost-effectiveness of NAT for HIV, HCV, and HBV in whole-blood donations. Transfusion, 2003, 43, 721-729.
43. BELL C.E., BOTTEMAN M.F., GAO X., WEISSFELD J.L., POSTMA M.J., PASHOS C.L., TRIULZI D., STAGINNUS U. - Cost-effectiveness of transfusion of platelet components prepared with pathogen inactivation treatment in the United States. Clin. Ther., 2003, 25, 2464-2486.
44. POSTMA M.J., VAN HULST M., DE WOLF J.T.M., BOTTEMAN M., STAGINNUS U. - Cost-effectiveness of pathogen inactivation for platelet transfusions in the Netherlands. Transfusion Med., 2005, 15, 379-387.
45. DEPASSE F., SENSEBE L., SEGHATCHIAN J., ANDREU G., SAMAMA M.M. - The influence of methylene blue light treatment and methylene blue removal filter on fibrinogen activity states and fibrin polymerisation indices. Transfus. Apher. Sci., 2005, 33, 63-69.
46. DE ALARCON P., BENJAMIN R., DUGDALE M., KESSLER C., SHOPNICK R., SMITH P., ABSHIRE T., HAMBLETON J., MATTHEW P., ORTIZ I., COHEN A., KONKLE B.A., STREIFF M., LEE M., WAGES D., CORASH L. - Fresh frozen plasma prepared with amotosalen HCl (S-59) photochemical pathogen inactivation: transfusion of patients with congenital coagulation factor deficiencies. Transfusion, 2005, 45, 1362-1372.
47. MURPHY S., SNYDER E., CABLE R., SLIGHTER S.J., STRAUSS R.G., MCCULLOUGH J., LIN J.S., CORASH L., CONLAN M.G., SPRINT Study Group -Platelet dose consistency and its effect on the number of platelet transfusions for support of thrombocytopenia: an analysis of the SPRINT trial of platelets photochemically treated with amotosalen HCl and ultraviolet A light. Transfusion, 2006, 46, 24-33.
48. MOEREMANS K., WARIE H., ANNEMANS L. - Assessment of the economic value of the INTERCEPT blood system in Belgium. Transfusion. Med., 2006, 16, 17-30.